1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Presented in part at the 68th Annual Scientific Meeting of the American College of Rheumatology, San Antonio, TX, October 2004.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Hydroxychloroquine in lupus pregnancy†
Article first published online: 30 OCT 2006
DOI: 10.1002/art.22159
Copyright © 2006 by the American College of Rheumatology
Additional Information
How to Cite
Clowse, M. E. B., Magder, L., Witter, F. and Petri, M. (2006), Hydroxychloroquine in lupus pregnancy. Arthritis & Rheumatism, 54: 3640–3647. doi: 10.1002/art.22159
- †
Publication History
- Issue published online: 30 OCT 2006
- Article first published online: 30 OCT 2006
- Manuscript Accepted: 11 JUL 2006
- Manuscript Received: 25 JAN 2006
Funded by
- NIH. Grant Numbers: R01-AR-43737, 5K12-HD-043446
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: M01-RR-00052
REFERENCES
- 1. Hydroxychloroquine: past, present, future. Lupus 1998; 7: 65–7.
- 2, , , , , , et al, and the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473–80.
- 3
- 4, , , , , , et al, and the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 80–5.
- 5, . Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993; 20: 650–6.
- 6, , , , . Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford) 1999; 38: 559–63.
- 7, , , . Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol 1974; 1: 293–8.
- 8, , . Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002; 29: 700–6.
- 9, , , , , , et al. Anti-inflammatory and immunosuppressive drugs and reproduction [review]. Arthritis Res Ther 2006; 8: 209–28.
- 10
- 11, , . Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature 1970; 227: 1257–8.
- 12, , , , , , et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207–11.
- 13, , , , , , et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401–4.
- 14, . Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23: 1715–8.
- 15, , , , , , et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases [letter]. Lancet 2001; 358: 813–4.
- 16, , , , . Antimalarial agents in pregnancy [letter]. Lancet 2002; 359: 524–5.
- 17, , . Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 19: 53–9.
- 18, , . Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34: 1538–45.
- 19, , , , , and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–40.
- 20, , , , . Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995; 40: 127–33.
- 21, , , . Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27: 771–9.
- 22, , , , . A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 163–8.
- 23, . Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121–30.
- 24, , . Review of ACR renal criteria in systemic lupus erythematosus. Lupus 2004; 13: 857–60.
- 25. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27: 499–505, v.
- 26, , , . Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107: 293–9.
- 27, , , . The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 514–21.
- 28
- 29, , , , , . Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486–8.
- 30, , , , . Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991; 8: 174–8.
- 31, , , , . Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: review of the literature. Autoimmun Rev 2005; 4: 111–5.
- 32, , , , . Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377–82.
- 33, , , , , , et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385–92.
- 34, , , , , , et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999; 8: 677–84.
- 35, , , , . Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392–7.